Oramed, Ltd.
ORMD-0801 8 mg
Type 2 Diabetes Mellitus
Countdown
292days
Phase 3 readout · Apr 25, 2027
What's at stake
Phase 3 trial results for ORMD-0801 8 mg in Type 2 Diabetes Mellitus are due Apr 25, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT06731075: Phase 3 trial, sponsor Oramed, Ltd., drug ORMD-0801 8 mg. Primary completion date 2027-04-25 (estimated).”